CLAIMS

1. A method of treating migraine comprising administering a therapeutic amount of a sumatriptan, frovatriptan or naratriptan condensation aerosol, having an MMAD less than 3 μm and less than 5% sumatriptan, frovatriptan or naratriptan degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.

2. The method of claim 1, wherein said condensation aerosol is formed by

a. volatilizing sumatriptan, frovatriptan or naratriptan under conditions effective to produce a heated vapor of the sumatriptan, frovatriptan or naratriptan, and

b. condensing the heated vapor of the sumatriptan, frovatriptan or naratriptan to form condensation aerosol particles.

3. The method according to claim 1, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second.

4. The method according to claim 1, wherein said therapeutic amount of sumatriptan condensation aerosol comprises between 5 mg and 40 mg of sumatriptan delivered in a single inspiration.

5. The method according to claim 1, wherein said therapeutic amount of frovatriptan condensation aerosol comprises between 0.5 mg and 4 mg of frovatriptan delivered in a single inspiration.

6. The method according to claim 1, wherein said therapeutic amount of naratriptan condensation aerosol comprises between 0.2 mg and 2 mg of naratriptan delivered in a single inspiration.

7. The method according to claim 2, wherein said administration results in a peak plasma concentration of said sumatriptan, frovatriptan or naratriptan in less than 0.1 hours.

8. The method according to claim 1, wherein at least 50% by weight of the condensation aerosol is amorphous in form.

9. A method of administering sumatriptan, frovatriptan or naratriptan to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of sumatriptan, frovatriptan or naratriptan having less than 5% sumatriptan, frovatriptan or naratriptan degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration is achieved in less than 0.1 hours.

10. A kit for delivering a drug aerosol comprising:

a) a thin coating of a sumatriptan, frovatriptan or naratriptan composition, and

b) a device for dispensing said thin coating as a condensation aerosol.

11. The kit of claim 10, wherein the device for dispensing said coating as a condensation aerosol comprises:

(a) a flow through enclosure,

(b) contained within the enclosure, a metal substrate with a foil-like surface and having a thin coating of sumatriptan, frovatriptan or naratriptan composition formed on the substrate surface,

(c) a power source that can be activated to heat the substrate to a temperature effective to volatilize the sumatriptan, frovatriptan or naratriptan composition contained in said coating, and

(d) inlet and exit portals through which air can be drawn through said device by inhalation,

wherein heating the substrate by activation of the power source is effective to form a sumatriptan, frovatriptan or naratriptan vapor containing less than 5% sumatriptan, frovatriptan or naratriptan degradation products, and drawing air through said chamber is effective to condense the sumatriptan, frovatriptan or naratriptan vapor to form aerosol particles wherein the aerosol has an MMAD of less than 3 microns.

12. The kit according to claim 11, wherein the heat for heating the substrate is generated by an exothermic chemical reaction.

13. The kit according to claim 12, wherein said exothermic chemical reaction is oxidation of combustible materials.

14. The kit according to claim 11, wherein the heat for heating the substrate is generated by passage of current through an electrical resistance element.

15. The kit according to claim 11, wherein said substrate has a surface area dimensioned to accommodate a therapeutic dose of sumatriptan, frovatriptan or naratriptan composition in said coating.

16. The kit according to claim 10, wherein a peak plasma concentration of sumatriptan, frovatriptan or naratriptan is obtained in less than 0.1 hours after delivery of condensation aerosol to the pulmonary system.

17. The kit of claim 10, further including instructions for use.